Skip to main content

Reneo Pharmaceuticals Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

OKUR$3.39+6.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (see signature page)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gregory J. Flesher and Jennifer P. Lam and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10‑K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

SignatureTitleDate
/s/ Gregory J. FlesherPresident and Chief Executive OfficerMarch 28, 2024
Gregory J. Flesher(Principal Executive Officer)
/s/ Jennifer P. LamSenior Vice President, Finance and AdministrationMarch 28, 2024
Jennifer P. Lam(Principal Financial and Accounting Officer)
/s/ Michael GreyExecutive ChairmanMarch 28, 2024
Michael Grey
/s/ Roshawn A. BluntDirectorMarch 28, 2024
Roshawn A. Blunt
/s/ Eric DubeDirectorMarch 28, 2024
Eric Dube, Ph. D.
/s/ Paul W. HoelscherDirectorMarch 28, 2024
Paul W. Hoelscher
/s/ Edward T. MathersDirectorMarch 28, 2024
Edward T. Mathers
/s/ Bali MuralidharDirectorMarch 28, 2024
Bali Muralidhar, M.D., Ph. D.
/s/ Niall O’DonnellDirectorMarch 28, 2024
Niall O’Donnell, Ph. D.
/s/ Stacey D. SeltzerDirectorMarch 28, 2024
Stacey D. Seltzer
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.